Non-functioning pituitary adenomas (NFPAs) are usually macroadenomas and display invasion into surrounding tissues. The treatment for invasive NFPAs is still challenging. This study describes the differential patterns of gene expression between invasive and non-invasive NFPAs and identifies novel biomarkers involved in invasion of NFPAs for diagnosis and treatment. Using gene microarray technology, we examined the gene expression profile and found 1160 differentially expressed messenger RNA (mRNA) between invasive and non-invasive NFPAs. Then, we examined the protein profile by liquid chromatography tandem mass spectrometry (LC-MS/MS) and found 433 differentially expressed proteins between invasive and non-invasive NFPAs. Subsequently, we integrated the proteomics and transcriptomics datasets and identified 29 common changed molecules. Through bioinformatics analysis using Ingenuity Pathway Analysis (IPA) software, we showed that the 29 molecules were enriched in 25 canonical signaling pathways, 25 molecular and cellular functions, and 2 networks. Eight genes were identified involved in the invasion function by the molecular and cellular functions analysis, including CAT, CLU, CHGA, EZR, KRT8, LIMA1, SH3GLB2 and SLC2A1. Furthermore, we validated the decreased CHGA expression and increased CLU expression in invasive NFPAs by qRT-PCR and Western blot. Our study demonstrated that integration of proteomics and transcriptomics could prove advantageous for accelerating tumor biomarker discovery and CHGA and CLU might be important novel biomarkers and therapeutic targets for invasion of NFPAs.
Non-functioning pituitary adenomas Proteomics Transcriptomics Clusterin Chromogranin A
This is a preview of subscription content, log in to check access.
The authors thank the subjects for donating DNA samples. The study is supported by the Research Special Fund for Public Welfare Industry of Health (201402008), the National High Technology Research and Development Program of China (863 Program), and the National Natural Science Foundation of China.
SYY and LCH participated in the study design and wrote the paper. SYY, LCH, and YTW carried out the experimental studies. JF and YZZ participated in manuscript revision. All authors read and approved the final manuscript.
Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 1998;19:798–827.PubMedGoogle Scholar
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–82.CrossRefGoogle Scholar
Selman WR, Laws EJ, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986;64:402–7.CrossRefPubMedGoogle Scholar
Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99–106. 106-107.CrossRefPubMedGoogle Scholar
Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122:803–11.CrossRefPubMedGoogle Scholar
Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology. 2015;101:87–104.Google Scholar
Feng J, Hong L, Wu Y, Li C, Wan H, Li G, et al. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas. J Neurooncol. 2014;119:307–15.CrossRefPubMedPubMedCentralGoogle Scholar
Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33:610–7. 617-618.CrossRefPubMedGoogle Scholar
Hsieh HC, Chen YT, Li JM, Chou TY, Chang MF, Huang SC, et al. Protein profilings in mouse liver regeneration after partial hepatectomy using iTRAQ technology. J Proteome Res. 2009;8:1004–13.CrossRefPubMedGoogle Scholar
Geng X, Wang G, Qin Y, Zang X, Li P, Geng Z, et al. ITRAQ-based quantitative proteomic analysis of the initiation of head regeneration in planarians. PLoS One. 2015;10, e132045.Google Scholar
Sandberg A, Lindell G, Kallstrom BN, Branca RM, Danielsson KG, Dahlberg M, et al. Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes. Mol Cell Proteomics. 2012;11:M112–16998.CrossRefPubMedPubMedCentralGoogle Scholar
Nie L, Wu G, Culley DE, Scholten JCM, Zhang W. Integrative analysis of transcriptomic and proteomic data: challenges, solutions and applications. Crit Rev Biotechnol. 2007;27:63–75.CrossRefPubMedGoogle Scholar
Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res. 2004;64:2962–8.CrossRefPubMedGoogle Scholar
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics. 2004;3:960–9.CrossRefPubMedGoogle Scholar
Riva C, Leutner M, Capella C, Usellini L, la Rosa S, Brianza MR, et al. Different expression of chromogranin a and chromogranin B in various types of pituitary adenomas. Zentralbl Pathol. 1993;139:165–70.PubMedGoogle Scholar
Portela-Gomes GM, Grimelius L, Wilander E, Stridsberg M. Granins and granin-related peptides in neuroendocrine tumours. Regul Pept. 2010;165:12–20.CrossRefPubMedGoogle Scholar
Bottoni P, De Michele T, Scatena R. A critical approach to clinical biochemistry of chromogranin a. Adv Exp Med Biol. 2015;867:317–23.CrossRefPubMedGoogle Scholar
Weisbrod AB, Zhang L, Jain M, Barak S, Quezado MM, Altered KE, et al. ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Horm Cancer. 2013;4:165–75.CrossRefPubMedPubMedCentralGoogle Scholar
Kimura N, Yoshida R, Shiraishi S, Pilichowska M, Ohuchi N. Chromogranin a and chromogranin B in noninvasive and invasive breast carcinoma. Endocr Pathol. 2002;13:117–22.CrossRefPubMedGoogle Scholar
Ekici AI, Eren B, Turkmen N, Comunoglu N, Fedakar R. Clusterin expression in non-neoplastic adenohypophyses and pituitary adenomas: Cytoplasmic clusterin localization in adenohypophysis is related to aging. Endocr Pathol. 2008;19:47–53.CrossRefPubMedGoogle Scholar
Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer. 2010;10:107.CrossRefPubMedPubMedCentralGoogle Scholar
Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 2009;21:704–11.CrossRefPubMedGoogle Scholar
Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O'Sullivan S, Treumann A, Gilmer JF, et al. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis. 2014;35:324–32.CrossRefPubMedGoogle Scholar
Chen D, Wang Y, Zhang K, Jiao X, Yan B, Liang J. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin. Int J Mol Sci. 2012;13:10594–607.CrossRefPubMedPubMedCentralGoogle Scholar
Wang Q, Cao W, Su Q, Liu Z, Zhang L. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells. World J Surg Oncol. 2014;12:124.CrossRefPubMedPubMedCentralGoogle Scholar
1.Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Beijing Institute for Brain Disorders Brain Tumor Center, China National Clinical Research Center for Neurological DiseasesCapital Medical UniversityBeijingChina
2.Beijing Neurosurgical InstituteCapital Medical UniversityBeijingChina